Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Reactogenicity of Pn-MAPS30plus Vaccine in Toddlers
NCT07406334Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK5459248 in bacterial pneumonia (2 arms), sponsored by GSK. Primary endpoints: Number of Participants with Solicited Administration site Adverse Events (AEs), Number of Participants with Solicited Systemic Adverse Events (AEs) and 3 more. Started May 2026; status: active, not recruiting.
02
Drugs
GSK5459248
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT07406334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406334.